William Towner to Anti-HIV Agents
This is a "connection" page, showing publications William Towner has written about Anti-HIV Agents.
Connection Strength
2.953
-
The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction. J Acquir Immune Defic Syndr. 2012 Jul 01; 60(3):321-7.
Score: 0.378
-
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States. J Acquir Immune Defic Syndr. 2010 Apr; 53(5):614-8.
Score: 0.324
-
Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. J Acquir Immune Defic Syndr. 2009 Aug 01; 51(4):367-73.
Score: 0.309
-
Fracture Risk and Association With TDF Use Among People With HIV in Large Integrated Health Systems. J Acquir Immune Defic Syndr. 2023 12 01; 94(4):341-348.
Score: 0.209
-
Project SLIP: Implementation of a PrEP Screening and Linkage Intervention in Primary Care. AIDS Behav. 2021 Aug; 25(8):2348-2357.
Score: 0.172
-
Association of raltegravir use with long-term health outcomes in HIV-infected patients: an observational post-licensure safety study in a large integrated healthcare system. HIV Clin Trials. 2018 10; 19(5):177-187.
Score: 0.147
-
Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI. HIV Clin Trials. 2017 05; 18(3):118-125.
Score: 0.133
-
Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals. J Acquir Immune Defic Syndr. 2016 Apr 01; 71(4):413-9.
Score: 0.123
-
The HIV Care Cascade Measured Over Time and by Age, Sex, and Race in a Large National Integrated Care System. AIDS Patient Care STDS. 2015 Nov; 29(11):582-90.
Score: 0.119
-
Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data. HIV Clin Trials. 2014 Mar-Apr; 15(2):51-6.
Score: 0.106
-
Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob Chemother. 2014 Jan; 69(1):12-20.
Score: 0.102
-
Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS. 2012 Nov 13; 26(17):2223-31.
Score: 0.097
-
Determination of optimized multidisciplinary care team for maximal antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2012 Jun 01; 60(2):183-90.
Score: 0.094
-
Short-term clinical outcomes among treatment-experienced HIV-positive patients with early low level viremia. AIDS Patient Care STDS. 2012 May; 26(5):253-5.
Score: 0.093
-
Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility. Antimicrob Agents Chemother. 2012 May; 56(5):2305-13.
Score: 0.092
-
A review of the safety and tolerability profile of the next-generation NNRTI etravirine. AIDS Res Hum Retroviruses. 2010 Jul; 26(7):725-33.
Score: 0.082
-
Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2010 Jan; 53(1):62-9.
Score: 0.080
-
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther. 2010; 15(7):1045-52.
Score: 0.080
-
Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations. Antimicrob Agents Chemother. 2009 Nov; 53(11):4869-78.
Score: 0.078
-
Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. HIV Clin Trials. 2008 Nov-Dec; 9(6):367-74.
Score: 0.073
-
HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2551-9.
Score: 0.023
-
HIV quality performance measures in a large integrated health care system. AIDS Patient Care STDS. 2011 Jan; 25(1):21-8.
Score: 0.021
-
Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study. HIV Clin Trials. 2008 May-Jun; 9(3):152-63.
Score: 0.018